Suppr超能文献

基于仙台病毒的非病毒基因转移方法:在实验性缺血中使用肝细胞生长因子和血管内皮生长因子基因进行成功的基因治疗。

HVJ-based non-viral gene transfer method: successful gene therapy using HGF and VEGF genes in experimental ischemia.

作者信息

Shimamura Munehisa, Sato Naoyuki, Yoshimura Shinichi, Kaneda Yasufumi, Morishita Ryuichi

机构信息

Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Japan.

出版信息

Front Biosci. 2006 Jan 1;11:753-9. doi: 10.2741/1833.

Abstract

VEGF and HGF are pleiotropic factors that regulate cell growth, cell motility, and morphogenesis of various types of cells. The receptors of these growth factors are expressed in neurons and endothelial cells, and are identified as neurotrophic, neuroprotective, and angiogenic factors. Indeed, gene therapy using viral vectors encoding the VEGF or HGF gene has been reported to be effective for preventing the expansion of ischemic injury. However, the safety issue of viral vectors is a major problem in clinical application. To overcome this problem, we have developed an HVJ-based non-viral vector, which achieves high-efficiency transfection rates of viral vectors with the safety of liposomes. This review discusses the feasibility of gene therapy using an HVJ-based non-viral vector containing the VEGF or HGF gene for cerebral ischemia.

摘要

血管内皮生长因子(VEGF)和肝细胞生长因子(HGF)是多效性因子,可调节各类细胞的生长、细胞运动及形态发生。这些生长因子的受体在神经元和内皮细胞中表达,并被鉴定为神经营养、神经保护和血管生成因子。事实上,据报道,使用编码VEGF或HGF基因的病毒载体进行基因治疗可有效预防缺血性损伤的扩大。然而,病毒载体的安全性问题是临床应用中的一个主要问题。为克服这一问题,我们开发了一种基于仙台病毒(HVJ)的非病毒载体,它在具备脂质体安全性的同时,实现了病毒载体的高效转染率。本文综述讨论了使用含有VEGF或HGF基因的基于HVJ的非病毒载体进行脑缺血基因治疗的可行性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验